Phase IV studies with currently licensed and WHO prequalified Sabin 2 mon to support the implementation of phase IV clinical trials in adults to evaluate the safety and reactogenicity of monovalent type 2 and trivalent Oral Polio Vaccine for future comparisons with data on new Oral Polio Vaccines